TBK1 and non-small cell lung carcinoma: For instance, TBK1 phosphorylates AGO2, which functions with double-stranded miRNA, to generate carcinogenic miRISC via the S417 site, a process related to the resistance of gefitinib targeted therapy in non-small cell lung cancer (22).